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Effects of huTNF-α, hIL-2 gene transfection on the expressionof 
MDR1, LRP gene in lung cancer
Su, Lei; Zhi, Xiuyi; Xu, Qingsheng; Liu, Baodong; Zhang, Yi; Wang, 
Ruotian; Hu, Mu; Liu, Lei; Qian, Kun 
Department of Thoracic Surgery, Xuan Wu Hospital of Capital Univer-
sity of Medical Science, Beijing, China
Background: To study the effects of huTNF-#&03b1; and hIL2 gene 
transfection on the expression of MDR1 and LRP genes in lung cancer 
cell lines. 
Methods: huTNF-#&03b1; and hIL2 gene plasmids were constructed 
and transfected into A549, GLC-282, H446 and H460 cells with lipo-
fectinmin. Positive clones were screened out by G418. The expressions 
of MDR1 and LRP genes were detected at mRNA level by reverse tran-
scription polymerase chain reaction (RT-PCR) in the non2transfected 
cells and the cloned cells. 
Results: MDR1 gene was positive in A549, GLC-82, H446 and H460 
cell lines, LRP gene was positive in A549, GLC-282 and H460 cell 
lines; The transfected cell lines expressed both huTNF-#&03b1; and 
hIL2 gene, and the A549, H446 and H460 cell lines transfected with 
hIL2 gene had no MDR1 expression at mRNA level compared with the 
non2transfected ones. 
Conclusion: MDR1 and LRP genes are expressed in lung cancer cell 
lines, which indicates the presence of intrinsic drug resistance before 
any form of therapy. MDR1 gene is not expressed in hIL2 transfected 
cell lines, which demonstrates that hIL2 gene modulates the MDR1 
gene expression at mRNA level, and may reverse the multidrug resis-
tance of lung cancer.
P2-053 BSTB: Molecular Targets Posters, Tue, Sept 4 
Establishment, identification and examination about the EGFR 
status of the lung cancer cell line
Xu, Chongrui; Guo, Ailin; Zhou, Qing; Dong, Song; Zhu, Jianquan; 
Lin, Jiaying; Yang, Jinji; Wu, Yilong 
Guangdong Provincial People’s Hospital, Guangzhou, China
Objective: To establish and identify a lung cancer cell line by primary 
culture and examine the EGFR status of the cell line.
Methods: The tumor cell was isolated from the tumor specimen by 
enzyme digestion and cultured in RPMI-1640. The cell line which had 
been cultured for over 60 passages was identiﬁed with cell grow curve, 
chromosome analysis, cell cycle by Flow Cytometry, soft agar colony 
forming test and tumorgenesis test in mice. After PCR ampliﬁcation 
of the 18, 19, 21 exon of EGFR gene and puriﬁcation of the PCR 
products, EGFR mutation of the exons was sequenced by using ABI 
3100. EGFR gene copy number was measured by Fluorescent In Situ 
Hybridization (FISH).
Results: One cell line was obtained from tumor specimen by enzyme 
digestion and had been cultured for more than 60 passages. The grow 
curve show that the doubling time of the cell line was 27.1 hours. The 
number of chromosome is 66-78 and the chromosome was triploid 
showing abnormal karyotypes. Cell cycle detected by Flow Cytometry 
show that there are 69.05% cells within G1 stage, 11.32% cells within 
G2 stage and 19.63% cells within S stage. The soft agar colony forming 
rate was 27.3% and the cell line exhibit great tumorigenesis activity in 
athymic mice. The sequences of exon 18, 19, 21 show that EGFR gene 
of the cell line was wild type and the gene copy number of the cell line 
detected by FISH was balanced polysomy.
Conclusions: The cell line from is identiﬁed to be the EGFR gene wild 
type and high copy number. EGFR mutation is not correspondence to 
the EGFR copy number. The patients with EGFR gene wild type and 
high copy number may have good response to EGFR-TKI.
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Combination treatment with arsenic trioxide and sulindac induces 
apoptosis of NCI-H157 human lung carcinoma cells via activation 
of mitogen-activated protein kinases
Yang, Sei-Hoon1 Kim, Hak-Ryul2 Kim, Eun Jung2 Jang, Hye Yeon2 
Jo, Hyang-Jeong2 Shim, Hyeok2 Lee, Kang Kyoo2 Park, Seong-Hoon2 
Park, Jung-Hyun2 Jeong, Eun-Taik2 
1 Department of Internal Medicine, Wonkwang University Hospital, 
Iksan, Korea 2 Wonkwang University Hospital, Iksan, Korea 
The arsenic trioxide (As203) has been introduced to the treatment of 
acute promyelocytic leukemia, and induced apoptosis in a variety of 
solid tumor cell lines. Non-steroidal anti-inﬂammatory drugs (NSAIDs) 
are known to enhance the responsiveness of tumor cells toward che-
motherapeutic drugs. We previously demonstrated that combination 
treatment with arsenic trioxide and sulindac augments their apoptotic 
potential in lung cancer cells through activation of caspase cascade 
and mitochondrial dysfunction. However, the previous mechanism of 
synergistic enhancement in tumoricidal activity is not clearly known 
yet. Herein, we demonstrated that combination treatment of As203 
and sulindac resulted in a synergistic augmentation of cytotoxicity 
and induced apoptosis in NCI-H157 lung cancer cells. Moreover the 
combination increased ROS levels compared with individual treatment. 
In addition, it further strongly induced HO-1 expression, activated 
stress-activated mitogen-activated protein kinases (MAPK), and DNA 
damage. Inhibition of either JNK or p38 kinase partially inhibited the 
augmented cell death and attenuated apoptosis by combination treat-
ment. In conclusion, the results showed that synergistic augmentation 
of cytotoxicity was partially involved by MAPK signaling pathway.
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A serum proteomic analysis of lung squamous cell carcinoma.
Borgia, Jeffrey A.; Frankenberger, Casey; Basu, Sanjib; Kaiser, Kelly 
A.; McCormack, Shannon E.; Faber, L. P.; Liptay, Michael J.; Bonomi, 
Philip D.; Coon, John S. 
Rush University Medical Center, Chicago, IL, USA
Background: Lung cancer accounts for the death of approximately 
160,000 Americans annually and is the most common cause of cancer 
mortality in developed nations. Comprising more than 30% of all can-
cer deaths in the U.S., mortality from lung cancer exceeds the estimated 
values for cancer of the breast, prostate, colon and rectum combined. 
Non-small cell lung cancer (NSCLC) is a heterogeneous collection of 
histological sub-types that accounts for approximately 80% of all lung 
cancer in the United States. The primary objective of this project is 
to identify new biomarkers for early squamous cell carcinoma (SCC) 
